Pharma News

Dentin is one of the most durable biological materials in the human body. Researchers from Charité - Universitätsmedizin Berlin were able to show that the reason for this can be traced to its nanostructures and specifically to the interactions between the organic and inorganic components. Measurements performed at BESSYII, the Helmholtz-Zentrum Berlin's synchrotron radiation source, showed that it is the mechanical coupling between the collagen protein fibers and mineral nanoparticles which renders dentin capable of withstanding extreme forces. Results from this research have been recently published in the journal Chemistry of Materials.

[adsense:336x280:8701650588]

Eating walnuts may change gut bacteria in a way that suppresses colon cancer, researchers led by UConn Health report in the journal Cancer Prevention Research.

Testing for metabolic changes in the blood could indicate whether a cancer drug is working as designed, a new study reports.Scientists have found that measuring how cancer treatment affects the levels of metabolites the building blocks of fats and proteins can be used to assess whether the drug is hitting its intended target.

Allergan plc, announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLBELLA® XC, for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21.

Janssen-Cilag International NV announced that the European Commission (EC) has approved the use of TREVICTA® (paliperidone palmitate a 3 monthly injection) for the maintenance treatment of schizophrenia in adult patients. TREVICTA will provide the longest dosing interval available for an antipsychotic medication in the European Union, allowing patients to maintain an optimal level of treatment in their blood with fewer administrations, compared to currently available antipsychotic treatments. This may improve outcomes for patients, carers and healthcare professionals. TREVICTA is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on XEPLION®¬, a 1-monthly paliperidone palmitate product that was approved in 2011 for the maintenance treatment of schizophrenia in the European Union.

Allergan plc, a leading global pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that they will donate 10,000 units of their hormonal IUD, Liletta (levonorgestrel-releasing intrauterine system) 52 mg, to the CDC Foundation. In addition, Allergan will donate over 40,000 one-month cycle packs of oral contraceptives. The contributions are in response to the outbreak of the Zika virus and are designed to help reduce unintended pregnancies in Puerto Rico, while the risk of the Zika virus is prevalent. Research has shown that pregnant women infected with the Zika virus are at risk of giving birth to infants born with microcephaly, a condition where babies' heads and brains are smaller and may not have developed properly during pregnancy.

Strides Shasun Limited has received the first to file tentative approval from the United States Food & Drug Administration (USFDA) for Roflumilast tablets, 500 mcg. The product received approval in 15 months under the new the Generic Drug User Fee Amendments of 2012 (GDUFA) goal date regime. The product can be launched earliest by January 2020.

According to the Confederation of Indian Industries ( CII),  Currently valued at around $ 4.6 billion ( at current forex rate of Rs. 67 per $, 30800 Crore.), the beauty and cosmetic industry is projected to grow between 18-20 per cent per annum in the next couple of years. There are many global giant players like Procter and Gamble, Loreal, Unilever etc. which have strong presence in Indian market. Apart from these MNC companies, many Indian companies like Himalaya , Godrej, ITC,  Emami, Marico, Dabur etc.

BioVentrix Inc., an emerging medical device company for less invasive treatment of heart failure (HF), announced that it has received a US Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial, named ALIVE (American Less Invasive Ventricular Enhancement). The trial is designed to demonstrate the safety and effectiveness of the Revivent TC TransCatheter; a hybrid closed-chest transcatheter procedure to treat patients suffering from ischemic cardiomyopathy by reshaping and restoring the left ventricle (LV).  This is accomplished by implanting micro-anchoring pairs in the LV to exclude scarred myocardium from the healthy tissue.

Dr Reddy’s Laboratories, a Rs.15,800 crore plus second largest pharma company in India, announced that its US subsidiary, Promius Pharma, LLC, U.S., launched Sernivo (betamethasone dipropionate) spray, 0.05% in the US. Sernivo spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.